AI
| Followers | 1699 |
| Posts | 205734 |
| Boards Moderated | 11 |
| Alias Born | 01/02/2008 |
Friday, February 08, 2013 9:09:16 AM
TZYM NEWS!!! BREAKOUT ALERT Charts --
Drugmaker Tranzyme Inc said it will explore strategic options, including a sale, less than two months after it stopped the second mid-stage trial of its drug for stomach paralysis.
The company retained Stifel as its financial adviser for the strategic review process, and said it has not made a decision to pursue any specific transaction.
Tranzyme went public in April 2011 at $4 per share and has a market value of $15 million. It has two other products in early testing.
http://www.reuters.com/article/2013/02/08/tranzyme-strategicoptions-idUSL4N0B85SK20130208?feedType=RSS&feedName=rbssHealthcareNews&rpc=43
daily and weekly charts
Drugmaker Tranzyme Inc said it will explore strategic options, including a sale, less than two months after it stopped the second mid-stage trial of its drug for stomach paralysis.
The company retained Stifel as its financial adviser for the strategic review process, and said it has not made a decision to pursue any specific transaction.
Tranzyme went public in April 2011 at $4 per share and has a market value of $15 million. It has two other products in early testing.
http://www.reuters.com/article/2013/02/08/tranzyme-strategicoptions-idUSL4N0B85SK20130208?feedType=RSS&feedName=rbssHealthcareNews&rpc=43
daily and weekly charts
January Effect 2013 Plays - follow them here: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82508852
"This is not an endorsement to buy or sell securities. Investing in securities carries with it very high risks. My posts /
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
